Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy

Experimental and Clinical Transplantation

Volumn 9, Issue 5, 2011, Pages 336-339

  Sayar, Hamid ^a   Sharfuddin, Asif A ^b   Taber, Tim E ^b   Mehta, Rakesh ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CML; Gleevec; Imatinib; Immunosuppression; Renal transplant

Indexed keywords

ALKALINE PHOSPHATASE; CORTICOSTEROID; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; SIDE EFFECT;

ADOLESCENT; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PIPERAZINES; PYRIMIDINES; TACROLIMUS; TIME FACTORS; UP-REGULATION;

EID: 80053962877     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7(2):147-156.
2. Battin J, Hehunstre JP, Bui NB, Auzerie J, Colle M. Chronic myeloid leukemia after immunosuppressive treatment for chronic nephropathy [in French]. Nouv Presse Med. 1976;5(39):2632.
3. Adler KR, Lempert N, Scharfman WB. Chronic granulocytic leukemia following successful renal transplantation. Cancer. 1978;41(6):2206-2208.
4. Lubynski R, Meyers AM, Disler PB, MacPhail AP, Myburgh JA, Katz J. Chronic granulocytic leukemia in a patient with a renal allograft. Arch Intern Med. 1978;138(9):1429-1430.
5. Mooy JM, Hagenouw-Taal JC, Lameijer LD, van Turnhout JM. Chronic granulocytic leukemia in a renal transplant recipient. Cancer. 1978;41(1):7-9.
6. Stein AM, Anthone R, Anthone S, Marinello MJ, Elwood CM, Bannerman RM. Chronic myelocytic leukemia in a young renal allografted patient. Transplantation. 1978;26(4):271-273.
7. Hilario R, Padre-Mendoza T, Albala MM. Chronic granulocytic leukemia and carcinoma of the cervix in situ following renal transplantation. Am J Med Sci. 1980;280(2):115-118.
8. Kirchner KA, Files JC, Didlake R, Raju S, Krueger RP. Chronic granulocytic leukemia after renal transplantation. Arch Intern Med. 1983;143(10):1984-1987.
9. Frist WH, Biggs VJ. Chronic myelogenous leukemia after lymphoid irradiation and heart transplantation. Ann Thorac Surg. 1994;57(1):214-216.
10. Pescovitz MD, Heerema NA, Jindal RM, Milgrom ML, Leapman SB, Filo RS. The natural history of chronic myelogenous leukemia in a renal transplant recipient. Transplantation. 1996;61(2):328-331.
11. Sanz L, Cervantes F, Esteve J, et al. Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography [in Spanish]. Sangre (Barc). 1996;41(5):391-393.
12. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant. 1998;2(1):56-63.
13. Mignozzi M, Picca S. Chronic myelogenous leukemia following kidney transplantation in a pediatric patient. Pediatr Nephrol. 2001;16(11):852-853.
14. Koca E, Cetiner D, Goker H, et al. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. Clin Nephrol. 2005;64(4):324-326.
15. Pelloso LA, Campos MG, Nascimento M, Silva MR, Pestana JO, Chauffaille Mde L. Chronic myeloid leukemia following kidney transplantation. Leuk Res. 2005;29(3):353-355.
16. Thierry A, Dreyfus B, Bridoux F, et al. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant. 2007;22(6):1791-1792.
17. Castillo-Rama M, Grande C, Martínez-Sanchez P, et al. Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant [in Spanish]. Nefrologia. 2009;29(6):604-607.
18. Concejero A, Chen CL, Wang CC, et al. Chronic myeloid leukemia after living donor liver transplantation. Transplantation. 2007;83(11):1521-1522.
19. le Coutre P, Reinke P, Neuhaus R, et al. BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients. Eur J Haematol. 2010;84(1):26-33.
20. Fontana V, Dudkiewicz P, Horstman LL, Tzakis AG, Ahn YS. Atypical chronic myeloid leukemia following organ transplants. Clinical Transplantation. 2008;22(2):258-261.
21. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022-4028.
22. van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ. 2010;340.
23. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60(2):183-189.
24. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92(9):3362-3367.